Karl Gubitz
Chief Financial OfficerMr. Karl Gubitz serves as Director at Forte Biosciences, Inc. since August 27, 2026. He serves as the Chief Financial Officer at argenx SE since June 1, 2021. He has an experience as a senior finance professional in the pharmaceutical industry at Pfizer, where he most recently served as Vice President of Finance within the Global Oncology business. At Pfizer, he successfully negotiated the commercialization model for tanezumab with Eli Lilly in all non-U.S. markets as well as the Myovant co-commercialization agreement for Orgovyx™. Within Pfizer, Mr. Gubitz has held country, regional and global positions and consistently delivered top-line growth. He has managed teams of over 250 colleagues in roles such as Vice President of Finance in the Global Internal Medicine business and Vice President of Finance, North America in the Global Innovative Products business. Prior to joining Pfizer in 2003, Mr. Gubitz held various management roles at PricewaterhouseCoopers. Mr. Gubitz holds a Master of Business Administration from Henley Management College in the United Kingdom, a Bachelor of Computing from the University of South Africa and a Bachelor of Commerce from the University of Pretoria.
Positions
- Company Nameargenx SEStock CodeARGXPositionChief Financial OfficerColleagues
- TVTimothy Van HauwermeirenCo-Founder & Non-Independent Non-Executive Chairman of the Board
- KMKaren MasseyCEO & Executive Director
- PUPeter UlrichtsChief Scientific Officer
- MMMalini MoorthyGeneral Counsel & Corporate Secretary
- AAAnthony A. RosenbergIndependent Vice Chairman
- HDHans de HaardCo-Founder & Member of Board Advisors
- ACAna CespedesIndependent Non-Executive Director
